Signals, Powered By EquityPandit
On Friday, Dr Reddys Laboratories said that it has completed the acquisition of select portfolio of established brands of Belgian firm UCB in India.
The company in a BSE filing said, “…with regard to acquisition of select portfolio of the established products business of UCB in India, Dr Reddy’s Laboratories Ltd…has concluded the transaction,” the company said in a filing to the BSE.
Dr Reddy’s has also said that the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with market leading brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M.
